Survey of the management of borderline ovarian tumors in the United Kingdom

Table 1 Different follow up protocols in the United Kingdom

Follow up (82% of centres)

Follow up for 5 yr at 3 and 9 mo, then 3 monthly for 2 yr then 6 monthly for 3 yr

Follow up for 5 yr, 3 monthly for the first 2 yr then 6 monthly onwards

Follow up for 5 yr at 6-12 mo, depending on the pathology

Follow up for 5 yr; 3 monthly for the first year, 4 monthly for the second year, 6 monthly for third year, and then annually for the fourth and fifth years

Follow up for 5 yr; every 6 months for 2 yr, then once a year for further 3 yr

Follow up for 3 yr, six monthly

All stage I patients are discharged. Patients with stages II and III disease are followed up: 3 monthly for 1 yr, 4 monthly for year 2 and 6 monthly for a third year

Stage IA fully staged are discharged, and all other patients have annual follow up for 10 yr

Stage IA completely staged are discharged and all other patients are followed up 6 monthly for 2 yr then annually up to 10 yr then every other year up to 20 yr

Stage IA fully staged are discharged, and all other patients are followed up monthly for 2 yr, then once in the third year and then discharged

Follow up is patient initiated. However, patients who retain their ovary are followed up by ultrasound every 6 mo

Follow up for patients who had fertility sparing surgery 6 monthly for life

Patients with Stage I disease have only one follow up visit. Patients with stage III are followed for several years

No follow up (18% of centres)

Table 2 Management of relapsed disease in different United Kingdom centres

Management	Percentage of centres (%)
Surgery only	53
Surgery followed by chemotherapy	13
Surgery followed by chemotherapy only if there is invasive disease	13
Chemotherapy followed by surgery	7
Chemotherapy only	7
Variable depending on MDT decision	7

MDT: Multidisciplinary team.

Table 3 Use of chemotherapy in treatment of borderline ovarian tumors in United Kingdom centres

Use of chemotherapy	Percentage of centres (%)
In the adjuvant setting
No chemotherapy used	46
Chemotherapy used only if there is invasive disease	23
Chemotherapy used	31
First line treatment of advanced (stage III or recurrent) disease
No chemotherapy used	8.3
Chemotherapy used	91.6

Chemotherapy used is carboplatin ± paclitaxel.